Predation threat modifies Pieris rapae performance and response to host plant quality.

Predators impact prey populations through both consumptive and non-consumptive effects, such as behavioral and physiological changes by prey in response to a predation threat. Additionally, various top-down (e.g. predator characteristics) and bottom-up factors (e.g. plant nutrients) may impact non-consumptive effects, yet little is understood about how these interact. We studied how host-plant choice, leaf consumption, and growth of an herbivore, Pieris rapae, were impacted by different levels of plant nitrogen (N) and two predator species representing varying degrees of threat, Hippodamia convergens (predator of early-instars) and Podisus maculiventris (predator of all-instars). We found that P. rapae adults and larvae made similar choices about bottom-up and top-down factors when threatened by two different predator species. Adults and larvae preferred high N plants when threatened by H. convergens, but plant N did not influence their host plant choice when threatened by P. maculiventris. Additionally, larvae consumed more leaf tissue and grew larger when threatened by H. convergens, but leaf tissue consumption and larval growth did not change under threat by P. maculiventris, suggesting that larvae may change their behavior if they are able to quickly outgrow life stages vulnerable to predation. These results indicate that top-down factors such as predator identity may determine how P. rapae modulate their responses to bottom-up factors such as host plant quality when utilizing anti-predator behaviors.

Inkjet-printed point-of-care immunoassay on a nanoscale polymer brush enables subpicomolar detection of analytes in blood.

The ELISA is the mainstay for sensitive and quantitative detection of protein analytes. Despite its utility, ELISA is time-consuming, resource-intensive, and infrastructure-dependent, limiting its availability in resource-limited regions. Here, we describe a self-contained immunoassay platform (the "D4 assay") that converts the sandwich immunoassay into a point-of-care test (POCT). The D4 assay is fabricated by inkjet printing assay reagents as microarrays on nanoscale polymer brushes on glass chips, so that all reagents are "on-chip," and these chips show durable storage stability without cold storage. The D4 assay can interrogate multiple analytes from a drop of blood, is compatible with a smartphone detector, and displays analytical figures of merit that are comparable to standard laboratory-based ELISA in whole blood. These attributes of the D4 POCT have the potential to democratize access to high-performance immunoassays in resource-limited settings without sacrificing their performance.

Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial.

OBJECTIVE: To evaluate the efficacy and safety of etoricoxib and indomethacin in the treatment of patients with acute gout. METHODS: A randomized, double-blind, active-comparator study was conducted at 42 sites. A total of 189 men and women (> or =18 years of age) who were experiencing an acute attack (< or =48 hours) of clinically diagnosed gout were treated for 8 days with etoricoxib, 120 mg/day (n = 103), or indomethacin, 50 mg 3 times a day (n = 86). The primary efficacy end point was the patient's assessment of pain in the study joint (0-4-point Likert scale) over days 2-5. Safety was assessed by adverse experiences (AEs) occurring during the trial. RESULTS: Etoricoxib demonstrated clinical efficacy comparable to that of indomethacin in terms of the patient's assessment of pain in the study joint. The difference in the mean change from baseline over days 2-5 was -0.08 (95% confidence interval -0.29, 0.13) (P = 0.46), which fell within the prespecified comparability bounds of -0.5 to 0.5. Secondary end points over the 8-day study, including the onset of efficacy, reduction in signs of inflammation, and patient's and investigator's global assessments of response to therapy, confirmed the comparable efficacy of the two treatments. The etoricoxib-treated patients had a numerically lower incidence of AEs (43.7%) than did the indomethacin-treated patients (57.0%) and a significantly lower incidence of drug-related AEs (16.5% versus 37.2%; P < 0.05). CONCLUSION: Etoricoxib at a dosage of 120 mg once daily was confirmed to be an effective treatment for acute gout. Etoricoxib was comparable in efficacy to indomethacin at a dosage of 50 mg 3 times daily, and it was generally safe and well tolerated.